Sign up for the QMED & MD+DI Daily newsletter.
Pressed for time? Here's the medtech news you need most, in one minute or less.
Amanda Pedersen
April 17, 2020
1 Min Read
Your time is valuable, so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.Image by OpenClipart-Vectors on Pixabay
How Abbott Became a Leader for COVID-19 Testing
Abbott tasked four independent R&D teams to develop four different types of testing solutions in response to the COVID-19 pandemic. So far the company has launched three of those tests – a molecular lab test, a rapid point-of-care test, and two different types of antibody tests. Three of those are already on the market and another antibody test is in the pipeline. All four tests have a different value proposition, said CEO Robert Ford.
Canaccord Genuity's annual survey of medtech executives suggests that telemedicine "is here and now" and will remain dominant as we emerge from the COVID-19 crisis, said analyst Jason Mills. What is not clear is how this transition will impact the medtech ecosystem near term as most of the industry plays in a fee-for-service reimbursement arena.
Ortho Clinical Picks Emergency Authorization for COVID-19 Antibody Test
Ortho Clinical Diagnostics secured emergency use authorization for its Vitros Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Calibrators. The COVID-19 total antibody test is designed to help determine who can responsibly be allowed back to work by aiding in the identification of previously exposed individuals who may have developed an immunity.
About the Author(s)
You May Also Like
